BiotechTube

ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis (CF)

Conditions

Cystic Fibrosis (CF)

Trial Timeline

Sep 20, 2021 → Jun 5, 2023

NCT ID
NCT04853368

About ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119

ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119 is a phase 2 stage product being developed by AbbVie for Cystic Fibrosis (CF). The current trial status is terminated. This product is registered under clinical trial identifier NCT04853368. Target conditions include Cystic Fibrosis (CF).

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis (CF) were approved

Approved (20) Terminated (7) Active (0)
✅CefiderocolShionogiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PancrelipaseAbbVieApproved
✅Tedizolid PO + Tedizolid IVMerckApproved
✅Alendronate + PlaceboMerckApproved
✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved
✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04853368Phase 2Terminated

Competing Products

20 competing products in Cystic Fibrosis (CF)

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
36
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
Enfortumab VedotinAstellas PharmaPhase 2
42
CefiderocolShionogiApproved
43
LenvatinibEisaiPhase 2
39
Lenvatinib + PembrolizumabEisaiPhase 2
39
CREONAbbVieApproved
43
Pancrelipase + PancrelipaseAbbVieApproved
43
Creon IR + Creon® (DR/GR)AbbViePhase 2
35
ABBV-CLS-628 + PlaceboAbbViePhase 2
42
Elagolix + PlaceboAbbViePhase 2
35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
35
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
29
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
40
AZD1236 + PlaceboAstraZenecaPhase 2
27
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
36
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
35
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
35